Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
Status:
Recruiting
Trial end date:
2024-12-29
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well the combination of binimetinib and
encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E
mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Giving binimetinib and encorafenib may work better
compared to the usual treatment in treating patients with pancreatic cancer and a somatic
BRAF V600E mutation.